05 Mar 2013, BioSpectrum Bureau , BioSpectrum
Singapore: Taiwan's PharmaEngine appointed Dr Alain Herrera as senior advisor for clinical strategy, operations, corporate strategy, licensing and alliance management.
Dr Herrera previously founded his own consultancy firm, Alain Oncologie Consulting. He was also VP, global oncology business strategy and development, sanofi-aventis. During his 10 years tenure he contributed to the worldwide registration of Oxaliplatin（Eloxatin）and Rasburicase（Fasturtec/Elitek), as well as the gastric and head and neck indications for Docetaxel（Taxotere). He was also chairman of Chiron Therapeutics Europe, MD at Pierre Fabre Oncology Laboratories and Roger Bellon (Rhône Poulenc).
"Dr Herrera, who was introduced to us by Professor Aimery de Gramont, chief of oncology department, Saint-Antoine Hospital, Paris, France, joined our scientific advisory board since 2008, and has been instrumental in advising our clinical and business strategies," said Dr C Grace Yeh, president and CEO, PharmaEngine.
"I am very pleased to have this opportunity to expand our collaboration with Dr Herrera, and I believe that his global pharmaceutical industry experience will assist us in fulfilling our goal to be recognized as one of the successful international pharmaceutical companies based in Taiwan," said Dr Yeh.
Dr Herrera said, "I am very happy to reinforce my collaboration with PharmaEngine. Since I started working with PharmaEngine more than four years ago, I realized that PharmaEngine has a professional team that not only successfully managed the worldwide development of PEP02, but also implemented a unique network of high level investigators from Taiwan, Asia, US and Europe."